Initial clinical data from the ongoing Phase 1 study of ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, including safety data, dosing regimen, and early clinical activity across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback